Alnylam stock soars to all-time high of $304.52

Alnylam Pharmaceuticals (NASDAQ:ALNY) Inc. has reached an unprecedented milestone as its stock price soared to an all-time high of $304.52. The company, now commanding a market capitalization of $39.6 billion, shows strong financial health according to InvestingPro analysis, with an impressive gross profit margin of 86%. This remarkable peak reflects a significant surge in investor confidence, underpinned by a robust 1-year return of 95.23%. The company’s groundbreaking advancements in RNA interference (RNAi) therapeutics have fueled this impressive growth, with revenue increasing 17.21% year-over-year. This performance has captured the attention of investors and solidified Alnylam’s position as a leader in the biopharmaceutical industry. The stock’s journey to this record value underscores a year of exceptional performance, with analysts setting price targets ranging from $212 to $500. For deeper insights into Alnylam’s valuation and growth prospects, including 11 additional ProTips, explore the comprehensive research available on InvestingPro.

In other recent news, Alnylam Pharmaceuticals has been the focus of several analyst reports and company updates. RBC Capital Markets reiterated an Outperform rating on Alnylam with a price target of $330, citing an optimistic outlook for the company’s quarterly performance and the strong initial uptake of their product Amvuttra. JPMorgan also maintained an Overweight rating and raised its price target to $330, highlighting positive IQVIA sales data for Amvuttra and anticipating a potential outperformance in the second quarter. Stifel analysts maintained a Buy rating with a $345 price target, expressing confidence in Amvuttra’s potential as a first-line therapy for cardiomyopathy, supported by HELIOS-B study data.

Alnylam’s shareholders recently approved key corporate governance changes, including an executive compensation plan and the re-election of four directors. The company also ratified PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2025. These developments follow Alnylam’s continued focus on RNA interference therapeutics, with upcoming phase 3 trials for their next-generation silencer, nucresiran. Analysts from RBC, JPMorgan, and Stifel have shown a positive outlook on the company’s strategic positioning and product pipeline, underscoring the potential market opportunities for Alnylam Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.